Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical A...(afety data from a cardiovascular outcome...),Health
Navigation Links
Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
Date:9/11/2007
afety data from a cardiovascular outcomes trial in its label.
Given the strength and consistency of the ACTOS data as demonstrated by the prospective studies, meta-analysis, and observational studies, Takeda remains confident in the ACTOS safety profile regarding the risk of macrovascular ischemic events.
'/>"/>
| Contact: Amy Losak amy.losak@ketchum.com 646-935-3917 Ketchum Source:Eurekalert |
Related medicine news :
1. Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab
2. Substituting soymilk for lactose intolerant students n schools: a great option
3. ACTOS Linked to Several Cardiovascular Benefits
4. Lactose-Intolerant kids need to take dairy products to meet nutrient requirements
5. Actos Linked To Bone Fractures In Diabetic Women
6. Largest Ever Study of Genetics Behind Common Diseases Published
7. A Just Published Book Promises To Guide Women Regarding Their Frequent UTI’
8. Findings on Dangerous Parasite, Toxoplasma Gondii Published
9. Siddha Medicine Texts to Be Published in English
10. Journal Recommends How To Improve The Performance Of Health Workers
11. Medical Journals should create awareness on Child survival
Post Your Comments:
Breaking Medicine News(10 mins):Health News:Anesiva Receives NASDAQ Listing Compliance Notice 2Health News:Anesiva Receives NASDAQ Listing Compliance Notice 3Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 2Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 3Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 4Health News:Consumers Choose Dallas Hospital for National Award Based on Quality and Image 2Health News:'Sandwich Generation' Avoids Unnecessary Stress While Tending to Aging Senior Parents 2Health News:OrderOnlineDrugs.com Makes Ordering Drugs Online Safe and Affordable 2
[0] Anesiva Receives NASDAQ Listing Compliance Notice[0] Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record[0] Consumers Choose Dallas Hospital for National Award Based on Quality and Image[0] 'Sandwich Generation' Avoids Unnecessary Stress While Tending to Aging Senior Parents[0] OrderOnlineDrugs.com Makes Ordering Drugs Online Safe and Affordable
Other Medicine News:Health News:Workplace e-mail intervention program helps people sit less and eat better 2Health News:Workplace e-mail intervention program helps people sit less and eat better 3Health News:LIFE 10th Anniversary Event Delivers Big Names and Big Dollars for Breast Cancer Fight 2Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 2Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 3Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 4Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 5Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 6Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 7Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 8Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 9Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 10Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 11Health News:Gentiva(R) Health Services Receives Nasdaq Notification Regarding Independent Director Requirement 2Health News:Gentiva(R) Health Services Receives Nasdaq Notification Regarding Independent Director Requirement 3Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 2Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 3Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 4Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 2Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 3Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 4
Workplace e-mail intervention program helps people sit less and eat betterLIFE 10th Anniversary Event Delivers Big Names and Big Dollars for Breast Cancer FightBMP Sunstone Reports First Quarter 2009 Financial ResultsGentiva(R) Health Services Receives Nasdaq Notification Regarding Independent Director RequirementTrubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual MeetingThe Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
Breaking Medicine Technology:AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays 2At Nearly $120 Million, The Hepatitis C Drug Market in Brazil is Among the Largest Emerging Pharmaceutical Markets for the Disease 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 3Studies Show Groundbreaking 22 25 Reduction in Depression Symptoms in 4 Hours 48837 1Studies Show Groundbreaking 22 25 Reduction in Depression Symptoms in 4 Hours 48837 2Studies Show Groundbreaking 22 25 Reduction in Depression Symptoms in 4 Hours 48837 3Cappella Inc Secures 2417 3 Million Series C Investment 12607 1Cappella Inc Secures 2417 3 Million Series C Investment 12607 2Cappella Inc Secures 2417 3 Million Series C Investment 12607 3Cappella Inc Secures 2417 3 Million Series C Investment 12607 4Cappella Inc Secures 2417 3 Million Series C Investment 12607 5Colleges communities combat off campus student drinking 48832 1Colleges communities combat off campus student drinking 48832 2
[0] AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays[0] At Nearly $120 Million, The Hepatitis C Drug Market in Brazil is Among the Largest Emerging Pharmaceutical Markets for the Disease[0] Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien
Other Medicine Technology:Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 2Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 3Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 4Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 5Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 6Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies 2Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |